FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
出版年份 2021 全文链接
标题
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
作者
关键词
-
出版物
Cancers
Volume 13, Issue 12, Pages 2968
出版商
MDPI AG
发表日期
2021-06-14
DOI
10.3390/cancers13122968
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling
- (2021) Harriet R. Ferguson et al. Cells
- Reciprocal priming between receptor tyrosine kinases at recycling endosomes orchestrates cellular signalling outputs
- (2021) Michael P Smith et al. EMBO JOURNAL
- Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
- (2020) Melanie A. Krook et al. MOLECULAR CANCER THERAPEUTICS
- Pemigatinib: First Approval
- (2020) Sheridan M. Hoy DRUGS
- Management of Hyperphosphatemia in End-Stage Renal Disease: A New Paradigm
- (2020) Anjay Rastogi et al. JOURNAL OF RENAL NUTRITION
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management
- (2020) Alison M. Boyce et al. Frontiers in Endocrinology
- Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, And Management Guidelines
- (2020) Mario E. Lacouture et al. ONCOLOGIST
- Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
- (2020) Ian M. Silverman et al. Cancer Discovery
- Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
- (2019) Claudia Fumarola et al. Frontiers in Oncology
- FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.
- (2019) Arlene O. Siefker-Radtke et al. JOURNAL OF CLINICAL ONCOLOGY
- TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma
- (2019) Lipika Goyal et al. Cancer Discovery
- Erdafitinib: First Global Approval
- (2019) Anthony Markham DRUGS
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity
- (2019) Sangeetha Palakurthi et al. Cancer Immunology Research
- FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma
- (2019) Amit Mahipal et al. CANCER TREATMENT REVIEWS
- Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
- (2019) Francesco Facchinetti et al. CLINICAL CANCER RESEARCH
- Dietary Management of Hyperphosphatemia
- (2018) Shivam Joshi et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor
- (2018) Krishna Arudra et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
- (2018) Sumanta K. Pal et al. Cancer Discovery
- Improvement in Hyperphosphatemia Using Phosphate Education and Planning Talks
- (2018) Alexander Brauer et al. JOURNAL OF RENAL NUTRITION
- LBA28Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
- (2018) M Javle et al. ANNALS OF ONCOLOGY
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- (2018) Vincenzo Mazzaferro et al. BRITISH JOURNAL OF CANCER
- Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors
- (2017) Sarah Bétrian et al. JAMA Dermatology
- Tumour-induced osteomalacia
- (2017) Salvatore Minisola et al. Nature Reviews Disease Primers
- Review article: bile acid diarrhoea - pathogenesis, diagnosis and management
- (2016) N. Mottacki et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Biophysical characterization of drug-resistant mutants of fibroblast growth factor receptor 1
- (2016) Kaito Yoza et al. GENES TO CELLS
- FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
- (2016) MASARU KATOH INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- (2016) Lipika Goyal et al. Cancer Discovery
- Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
- (2016) R. F. Sweis et al. Cancer Immunology Research
- Fibroblast Growth Factor Signaling in Metabolic Regulation
- (2016) Vera J. M. Nies et al. Frontiers in Endocrinology
- mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma
- (2015) T Scheller et al. BRITISH JOURNAL OF CANCER
- Targeting FGFR Signaling in Cancer
- (2015) M. Touat et al. CLINICAL CANCER RESEARCH
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation
- (2015) Maria-Giuseppina Procopio et al. NATURE CELL BIOLOGY
- Nonadherence to Medication Therapy in Haemodialysis Patients: A Systematic Review
- (2015) Saurav Ghimire et al. PLoS One
- Reductions in Myeloid-Derived Suppressor Cells and Lung Metastases using AZD4547 Treatment of a Metastatic Murine Breast Tumor Model
- (2014) Li Liu et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation
- (2014) Julienne E. Bower et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients
- (2014) Jürgen Floege et al. KIDNEY INTERNATIONAL
- Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis
- (2014) Sunday S. Oladipupo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
- (2013) R. Dienstmann et al. ANNALS OF ONCOLOGY
- Molecular Mechanisms of Fibroblast Growth Factor Signaling in Physiology and Pathology
- (2013) A. A. Belov et al. Cold Spring Harbor Perspectives in Biology
- Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
- (2013) Maria Vittoria Dieci et al. Cancer Discovery
- Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
- (2012) V Chell et al. ONCOGENE
- Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
- (2011) C. Lieu et al. CLINICAL CANCER RESEARCH
- Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer
- (2011) Francesco Bertolini et al. DRUG DISCOVERY TODAY
- FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways
- (2011) Ai-Luen Wu et al. PLoS One
- A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
- (2010) Wenjun Zhou et al. CHEMISTRY & BIOLOGY
- Vegetarian Compared with Meat Dietary Protein Source and Phosphorus Homeostasis in Chronic Kidney Disease
- (2010) S. M. Moe et al. Clinical Journal of the American Society of Nephrology
- Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling
- (2010) C. M. Fillmore et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Role of Fibroblast Growth Factors in Tumor Growth
- (2009) M. Korc et al. CURRENT CANCER DRUG TARGETS
- Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
- (2009) Michael G. Gartside et al. MOLECULAR CANCER RESEARCH
- Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression
- (2008) Kwang-Hoon Song et al. HEPATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started